|
| 36824825 | Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures. | bioRxiv | 2023 |
| 37986997 | Biologic and clinical features of childhood gamma delta T-ALL: identification of STAG2/LMO2 γδ T-ALL as an extremely high risk leukemia in the very young. | medRxiv | 2023 |
| 37575398 | Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells. | Bio Protoc | 2023 |
| 37729596 | Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL. | J Clin Oncol | 2023 |
| 37303270 | An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. | Clin Pharmacol Ther | 2023 |
| 37199744 | Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma. | Cancer Chemother Pharmacol | 2023 |
| 36604538 | Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. | Nat Med | 2023 |
| 36798219 | Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. | medRxiv | 2023 |
| 34196166 | Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. | Haematologica | 2022 |
| 35671062 | Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. | Blood Adv | 2022 |
| 35537468 | Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. | Annu Rev Genomics Hum Genet | 2022 |
| 36104354 | Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. | Nat Commun | 2022 |
| 36228116 | Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts. | J Am Med Inform Assoc | 2022 |
| 36028659 | Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia. | Leukemia | 2022 |
| 36050548 | The genomic landscape of pediatric acute lymphoblastic leukemia. | Nat Genet | 2022 |
| 34866312 | Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy. | Pediatr Blood Cancer | 2022 |
| 34693927 | Incorporating G6PD genotyping to identify patients with G6PD deficiency. | Pharmacogenet Genomics | 2022 |
| 33124053 | Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. | Clin Pharmacol Ther | 2021 |
| 33742760 | Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. | Clin Transl Sci | 2021 |
| 33714976 | Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. | Leukemia | 2021 |
| 33598942 | Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. | Cancer | 2021 |
| 34103329 | Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia. | Cancer Discov | 2021 |
| 34151288 | Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. | Nat Cancer | 2021 |
| 34318925 | Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. | Clin Pharmacol Ther | 2021 |
| 34239401 | Evaluation of Aminophylline for the Treatment of Acute Kidney Injury in Pediatric Hematology/Oncology Patients. | J Pediatr Pharmacol Ther | 2021 |
| 33387367 | Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. | Clin Pharmacol Ther | 2021 |
| 31341243 | Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination. | Genet Med | 2020 |
| 33164984 | Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo. | J Clin Invest | 2020 |
| 32809242 | Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. | Cancer | 2020 |
| 32710497 | Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. | Cancer Med | 2020 |
| 31612640 | Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. | Pediatr Blood Cancer | 2020 |
| 30467830 | The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children. | Clin Pharmacol Ther | 2019 |
| 31694285 | <i>GSTM1</i> and Liver Iron Content in Children with Sickle Cell Anemia and Iron Overload. | J Clin Med | 2019 |
| 31188727 | Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. | J Clin Oncol | 2019 |
| 30819904 | Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. | Haematologica | 2019 |
| 30405880 | Genome-wide association analysis identifies SNPs predictive of <i>in vitro</i> leukemic cell sensitivity to cytarabine in pediatric AML. | Oncotarget | 2018 |
| 29866879 | Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. | Antimicrob Agents Chemother | 2018 |
| 30088438 | Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. | Pharmacogenomics | 2018 |
| 27564568 | Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. | Clin Pharmacol Ther | 2017 |
| 28274984 | Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. | Am J Health Syst Pharm | 2017 |
| 27618250 | An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. | Clin Pharmacol Ther | 2017 |
| 27967321 | The impact of the UGT1A1*60 allele on bilirubin serum concentrations. | Pharmacogenomics | 2017 |
| 26704670 | Vincristine pharmacogenomics: 'winner's curse' or a different phenotype? | Pharmacogenet Genomics | 2016 |
| 26488798 | Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion. | Pediatr Blood Cancer | 2016 |
| 26366682 | Clinical significance of in vivo cytarabine-induced gene expression signature in AML. | Leuk Lymphoma | 2016 |
| 27766934 | CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints. | BMC Bioinformatics | 2016 |
| 27311679 | Comparison of genome sequencing and clinical genotyping for pharmacogenes. | Clin Pharmacol Ther | 2016 |
| 27335380 | Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. | Pediatrics | 2016 |
| 25292429 | Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. | Annu Rev Pharmacol Toxicol | 2015 |
| 25938942 | NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. | Nat Genet | 2015 |